Literature DB >> 33037305

Population-specific genetic background for the OPRM1 variant rs1799971 (118A>G): implications for genomic medicine and functional analysis.

Orna Levran1, Mary Jeanne Kreek2.   

Abstract

The mu-opioid receptor (MOR, OPRM1) has important roles in diverse functions including reward, addiction, and response to pain treatment. SNP rs1799971 (118A > G, N40D) which occur at a high frequency (40-60%) in Asia and moderate frequency (15%) in samples of European ancestry, is the only common coding variant in the canonical transcript, in non-African populations. Despite extensive studies, the molecular consequences of this variation remained unresolved. The aim of this study was to determine the genetic background of the OPRM1 region of 118G in four representative populations and to assess its potential modulatory effect. Seven common haplotypes with distinct population distribution were identified based on seven SNPs. Three haplotypes carry the 118G and additional highly linked regulatory SNPs (e.g., rs9383689) that could modulate the effect of 118G. Extended analysis in the 1000 Genomes database (n = 2504) revealed a common East Asian-specific haplotype with a different genetic background in which there are no variant alleles for an upstream LD block tagged by the eQTL rs9397171. The major European haplotype specifically includes the eQTL intronic SNP rs62436463 that must have arisen after the split between European and Asian populations. Differentiating between the effect of 118G and these SNPs requires specific experimental approaches. The analysis also revealed a significant increase in two 118A haplotypes with eQTL SNPs associated with drug addiction (rs510769) and obesity (rs9478496) in populations with native Mexican ancestry. Future studies are required to assess the clinical implication of these findings.
© 2020. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33037305     DOI: 10.1038/s41380-020-00902-4

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  39 in total

Review 1.  Mu opioids and their receptors: evolution of a concept.

Authors:  Gavril W Pasternak; Ying-Xian Pan
Journal:  Pharmacol Rev       Date:  2013-09-27       Impact factor: 25.468

Review 2.  Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics.

Authors:  Mary Jeanne Kreek; Orna Levran; Brian Reed; Stefan D Schlussman; Yan Zhou; Eduardo R Butelman
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

Review 3.  A review of opioid addiction genetics.

Authors:  Richard C Crist; Benjamin C Reiner; Wade H Berrettini
Journal:  Curr Opin Psychol       Date:  2018-08-09

Review 4.  The genetics of the opioid system and specific drug addictions.

Authors:  Orna Levran; Vadim Yuferov; Mary Jeanne Kreek
Journal:  Hum Genet       Date:  2012-05-01       Impact factor: 4.132

5.  The Relevance of the OPRM1 118A>G Genetic Variant for Opioid Requirement in Pain Treatment: A Meta-Analysis.

Authors:  Xueying Zhang; Yongxin Liang; Nannan Zhang; Ying Yan; Shanling Liu; Hao Fengxi; Dai Zhao; Haichen Chu
Journal:  Pain Physician       Date:  2019-07       Impact factor: 4.965

Review 6.  Human Disease Variation in the Light of Population Genomics.

Authors:  Ana Prohaska; Fernando Racimo; Andrew J Schork; Martin Sikora; Aaron J Stern; Melissa Ilardo; Morten Erik Allentoft; Lasse Folkersen; Alfonso Buil; J Víctor Moreno-Mayar; Thorfinn Korneliussen; Daniel Geschwind; Andrés Ingason; Thomas Werge; Rasmus Nielsen; Eske Willerslev
Journal:  Cell       Date:  2019-03-21       Impact factor: 41.582

Review 7.  OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models.

Authors:  Stephen D Mague; Julie A Blendy
Journal:  Drug Alcohol Depend       Date:  2010-01-13       Impact factor: 4.492

8.  Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction.

Authors:  C Bond; K S LaForge; M Tian; D Melia; S Zhang; L Borg; J Gong; J Schluger; J A Strong; S M Leal; J A Tischfield; M J Kreek; L Yu
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

9.  Human population genetic structure detected by pain-related mu opioid receptor gene polymorphisms.

Authors:  Eduardo Javier López Soto; Cecilia Inés Catanesi
Journal:  Genet Mol Biol       Date:  2015-05-01       Impact factor: 1.771

Review 10.  Molecular Imaging of Opioid and Dopamine Systems: Insights Into the Pharmacogenetics of Opioid Use Disorders.

Authors:  Jamie A Burns; Danielle S Kroll; Dana E Feldman; Christopher Kure Liu; Peter Manza; Corinde E Wiers; Nora D Volkow; Gene-Jack Wang
Journal:  Front Psychiatry       Date:  2019-09-18       Impact factor: 4.157

View more
  3 in total

1.  Mu opioid receptor gene variant modulates subjective response to smoked cannabis.

Authors:  Zoe Bourgault; Justin Matheson; Robert E Mann; Bruna Brands; Christine M Wickens; Arun K Tiwari; Clement C Zai; James Kennedy; Bernard Le Foll
Journal:  Am J Transl Res       Date:  2022-01-15       Impact factor: 4.060

2.  Associations of the A118G OPRM1 polymorphism with sociotropy and interpersonal sensitivity.

Authors:  Akihito Suzuki; Toshinori Shirata; Keisuke Noto; Yoshihiko Matsumoto; Haruka Muraosa; Mio Abe; Kaoru Goto; Koichi Otani
Journal:  Brain Behav       Date:  2022-06-27       Impact factor: 3.405

3.  Multi-trait genome-wide association study of opioid addiction: OPRM1 and beyond.

Authors:  Nathan Gaddis; Ravi Mathur; Eric Otto Johnson; Jesse Marks; Linran Zhou; Bryan Quach; Alex Waldrop; Orna Levran; Arpana Agrawal; Matthew Randesi; Miriam Adelson; Paul W Jeffries; Nicholas G Martin; Louisa Degenhardt; Grant W Montgomery; Leah Wetherill; Dongbing Lai; Kathleen Bucholz; Tatiana Foroud; Bernice Porjesz; Valgerdur Runarsdottir; Thorarinn Tyrfingsson; Gudmundur Einarsson; Daniel F Gudbjartsson; Bradley Todd Webb; Richard C Crist; Henry R Kranzler; Richard Sherva; Hang Zhou; Gary Hulse; Dieter Wildenauer; Erin Kelty; John Attia; Elizabeth G Holliday; Mark McEvoy; Rodney J Scott; Sibylle G Schwab; Brion S Maher; Richard Gruza; Mary Jeanne Kreek; Elliot C Nelson; Thorgeir Thorgeirsson; Kari Stefansson; Wade H Berrettini; Joel Gelernter; Howard J Edenberg; Laura Bierut; Dana B Hancock
Journal:  Sci Rep       Date:  2022-10-07       Impact factor: 4.996

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.